Pacira BioSciences (PCRX) Q4 2025 earnings review
Record Top-Line Obscures Severe Expense Pressures
Pacira delivered record fourth-quarter revenue of $196.9M (+5% YoY), driven by a solid 7% volume growth in its flagship product, EXPAREL. However, the narrative of commercial success is heavily undermined by a collapse in profitability. Unanticipated litigation and business development costs caused SG&A to spike 27% YoY, while R&D surged 57% due to in-licensing fees. Consequently, Adjusted EBITDA reversed sharply, plunging 38% YoY to $38.7M. While management's 2026 guidance predicts continued top-line growth, it implies gross margin compression, signaling that earnings leverage remains a distant prospect.
🐂 Bull Case
EXPAREL achieved 7% volume growth in Q4, validating management's market access strategy, GPO contracting, and NOPAIN Act tailwinds. It marks the strongest Q4 volume performance in three years.
The company aggressively bought back 5.9 million shares (nearly 13% of basic shares outstanding) for $150M in 2025, reflecting strong conviction in the pipeline and baseline cash generation.
🐻 Bear Case
Despite a record 81% non-GAAP gross margin for the year, Pacira completely failed to drop this to the bottom line in Q4. Runaway operating expenses erased the margin benefits.
Despite a highly touted commercial partnership with J&J MedTech initiated in Q3 to expand reach, ZILRETTA Q4 sales were absolutely flat YoY at $33.0M, exposing execution risks.
⚖️ Verdict: 🔴
Bearish. While EXPAREL volume growth is a tangible positive, the sudden spike in opaque 'unanticipated' expenses and guidance that projects gross margin degradation in 2026 raises massive red flags regarding management's cost control and long-term earnings visibility.
Key Themes
Operating Expense Explosion Crushes Margins
A reversing trend in profitability emerged as Total Operating Expenses spiked 20% YoY to $194.5M in Q4. SG&A jumped 28% to $101.6M, which management vaguely attributed to 'unanticipated costs associated with business development due diligence and litigation.' When one-off or unanticipated expenses begin consuming all top-line growth, quality of earnings deteriorates significantly.
EXPAREL Volume Growth Outpaces Revenue
EXPAREL volume is accelerating, growing 7% in Q4 (and 6% for the full year). However, net sales grew only 5% YoY in Q4 to $155.8M. The persistent gap between volume and revenue growth indicates that GPO discounting and vial mix shifts continue to act as a pricing headwind, diluting the financial impact of commercial success.
ZILRETTA Lags Despite Major Partnership
ZILRETTA sales are stable but stagnant, coming in at $33.0M for Q4 (vs $33.1M last year) and $116.6M for FY25 (down 1% YoY). A major J&J MedTech co-promotion agreement launched earlier in the year was supposed to 'double the commercial footprint,' but the promised acceleration has completely failed to materialize in the numbers so far.
Pipeline Expansion via PCRX-2002
Innovation continues as Pacira in-licensed PCRX-2002 (formerly AMT-143) from AmacaThera, triggering a $5.0M upfront R&D charge. This long-acting ropivacaine formulation complements EXPAREL and aligns with the company's '5x30' strategy to build a broader non-opioid musculoskeletal pain portfolio.
Macro Pressures on Pricing and Volumes
The broader macro environment shows signs of pressure. The company continues to navigate sluggish elective surgical procedure volumes across the industry. Furthermore, expanding market access through large GPO contracts comes at a cost, embedding mid-single-digit pricing discounts that cap true revenue realization.
Other KPIs
Reversing. Down drastically from $16.0M in 24Q4. Diluted EPS collapsed from $0.34 to $0.04. The collapse was driven entirely by surging below-the-line operating expenses, wiping out a healthy $9.2 million year-over-year increase in gross profit.
Accelerating. An 8% increase YoY, representing the highest quarterly sales figure of the year (up sequentially from $6.5M in Q3 and $5.6M in Q2). The dedicated sales force transition appears to be finally gaining traction.
Guidance
Stable. The midpoint of $757.5M implies a 4.3% YoY growth rate over FY25's $726.4M. This suggests that management expects current moderate growth trends to continue, rather than a massive immediate inflection from the NOPAIN Act.
Accelerating. The midpoint of $610M represents a 6% YoY growth rate compared to the 5% revenue growth delivered in FY25. This likely reflects the continued rollout of NOPAIN Act reimbursements offsetting GPO discounting.
Decelerating. FY25 Non-GAAP Gross Margin finished at an impressive 81% due to massive manufacturing efficiencies (decommissioning the 45-liter suite). Guiding down to 77-79% suggests the company is burning through low-cost inventory built up in 2025, and standardizing at a slightly lower structural margin.
Stable. Compares to $326.9M in Non-GAAP SG&A for FY25. It suggests that while Q4 2025 experienced severe one-off litigation/BD shocks, standard operating costs should normalize moving forward.
Key Questions
Visibility on 'Unanticipated' Expenses
You cited 'unanticipated costs associated with business development due diligence and litigation' as the driver for the massive Q4 SG&A miss. What exactly were these items, and what structural changes are being made to ensure tighter cost controls in 2026?
ZILRETTA Turnaround Timeline
Despite launching the J&J MedTech partnership to triple the commercial footprint, ZILRETTA sales were flat YoY in Q4. What specific leading indicators are you seeing that prove this partnership is actually working?
Gross Margin Step-Down
You achieved a stellar 81% non-GAAP gross margin in FY25, yet you are guiding 2026 down to 77-79%. Can you bridge this deceleration and explain how much is related to inventory sell-through versus structural changes in manufacturing yields?
LG Chem Partnership Economics
Regarding the new LG Chem partnership in the Asian-Pacific markets, can you provide color on the timeline for milestone payments and the expected long-term margin profile of the transfer price and tiered royalties?